Cellectis Pivots to In Vivo Gene Editing, Exits CAR-T Programs
CLLS is trading near its 52-week low of $2.35 (11% below the low) on elevated volume (3.5× avg).
Summary
Cellectis announced a strategic transformation to an in vivo gene editing company, advancing .HEAL-101 and .HEAL-201 for severe dyslipidemias while exiting lasme-cel and eti-cel development. The realignment targets cash runway extension into H2 2028.
Key Events · Product Development and Regulatory · CLLS
-
Strategic Pivot to In Vivo Gene Editing
Board approved on September 11, 2026 a transformation to focus on in vivo gene editing for chronic diseases, advancing .HEAL-101 (APOC3 base editing for severe hypertriglyceridemia) and .HEAL-201 (PCSK9 epigenetic editing for severe hypercholesterolemia).
-
Exit from CAR-T Programs
Cellectis will cease development of lasme-cel and eti-cel due to a materially changed competitive landscape in B-ALL and NHL, including lower relapse rates from frontline advances and competition from bispecifics and in vivo CAR-T, while seeking strategic partnering opportunities.
-
Cash Runway Extension
Operational realignment, including headcount reductions subject to works council consultation, is designed to extend cash runway into H2 2028, excluding any impact from potential future partnering of lasme-cel or eti-cel.
-
Clinical Data Timelines
Preliminary Phase 1 data from investigator-initiated trials in China planned for H2 2027 (.HEAL-101) and H1 2028 (.HEAL-201).
Analysis · CLLS · Life Sciences
Cellectis is abandoning its allogeneic CAR-T programs lasme-cel and eti-cel after concluding the competitive landscape for B-ALL and NHL has deteriorated, and is pivoting entirely to in vivo gene editing with two lead programs targeting severe dyslipidemias. The company will realign its organization and extend its cash runway into H2 2028, but the exit from its most advanced clinical assets represents a major strategic reset that removes near-term commercial catalysts and shifts value to earlier-stage preclinical programs.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLLS was trading at $2.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $220.9M. The 52-week trading range was $2.35 to $5.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.